Disease relevance of NSC651

• 2,3-Dihydrophthalazine-1,4-dione was active in vivo against L1210 leukemia, Lewis lung and Ehrlich ascites carcinoma growth [1].
• 2,3-Dihydrophthalazine-1,4-dione derivatives demonstrated potent cytotoxicity against the growth of murine leukemia cells and human single cell suspension, i.e. Tmolt3 leukemia and HeLa-S3, as well as colon adenocarcinoma and KB nasopharynx [1].
• Thus, alpha,beta-unsaturated peptidomimetics, anilides, metal-conjugated compounds, boronic acids, quinolinecarboxylate derivatives, thiophenecarboxylates, phthalhydrazide-substituted ketoglutamine analogues, isatin and natural products have been identified as potent inhibitors of the SARS-CoV main protease [2].

High impact information on NSC651

• The 2D assembly of phthalhydrazide 1 and aminopyrimidine 2 derivatives equipped with C16 and C8 alkyl chains, respectively, on highly ordered pyrolytic graphite (HOPG) was studied by scanning tunneling microscopy [3].
• The luminol analogue phthalhydrazide, which was suggested by Merényi and Lind as a reliable OH. detector, can replace luminol only in phosphate buffer, and thus turns out to be very specific indeed for free OH. [4].
• 2,3-Dihydrophthalazine-1,4-dione effectively lowers serum levels of cholesterol and triglycerides in Sprague Dawley rats after two weeks, after which the cholesterol levels continued to decline [5].
• Effects of 2,3-dihydrophthalazine-1,4-dione on Sprague Dawley rats lipid metabolism and serum lipoproteins [5].

Associations of NSC651 with other chemical compounds

• Rate limiting enzymes involved in de novo cholesterol, fatty acid and triglyceride synthesis were inhibited by 2,3-dihydrophthalazine-1,4-dione after eight weeks of administration [5].

References